Perspective Therapeutics, Inc. updated its corporate presentation on April 1, 2026, highlighting its 212Pb-based radiopharmaceutical pipeline including ongoing Phase 1/2a trials for VMT-α-NET, VMT01, and PSV359.
Key takeaways
Updated corporate presentation filed as Exhibit 99.1 detailing proprietary radioligand platform and 212Pb isotope advantages.
VMT-α-NET in Phase 1/2a for SSTR2+ neuroendocrine tumors shows compelling anti-tumor activity and best-in-class safety.
VMT01 in Phase 1/2a for MC1R-targeting melanoma demonstrates preliminary anti-tumor activity and tolerability.
PSV359 in Phase 1/2a for FAP-α-targeting solid tumors with improved tumor retention.
Phase 1/2 data expected across all three clinical programs in 2026.